title: Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy.
authors.affiliation: *Imperial College London, London, United Kingdom †Research Department of Infection and Population Health, University College London, London, United Kingdom ‡St. Stephen's Centre, Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom §TB Service, University College London Hospitals NHS Foundation Trust, London, United Kingdom.
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Rawson
authors.forename: Nataliya
authors.initials: N
authors.lastname: Brima
authors.forename: Fahad
authors.initials: F
authors.lastname: Almajid
authors.forename: Anton L
authors.initials: AL
authors.lastname: Pozniak
authors.forename: Azara
authors.initials: A
authors.lastname: Janmohamed
authors.forename: Sundhiya
authors.initials: S
authors.lastname: Mandalia
authors.forename: Sheena
authors.initials: S
authors.lastname: Basnayake
authors.forename: Lusha
authors.initials: L
authors.lastname: Kellgren
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Copas
authors.forename: Robert F
authors.initials: RF
authors.lastname: Miller
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D017828:Rifabutin / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy*; D006113:United Kingdom
chemical_list: D000995:Antitubercular Agents; D017828:Rifabutin; D012293:Rifampin